To evaluate the impact of SGLT2 inhibitor treatment on cardiomyocyte size and adipocyte hypertrophy as indicators of cardiac hypertrophy and proinflammatory EAT quality in obesity-related MHD, respectively, we analyzed WGA-stained sections of heart tissue and H&E-stained sections of EAT from HFHS+EMPA and HFHS mice. The gene discussed is SLC5A2; the disease is cardiac hypertrophy.